Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and...
-
Upload
rodney-bailey -
Category
Documents
-
view
215 -
download
1
Transcript of Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and...
![Page 1: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/1.jpg)
Pre Liver Transplant Evaluation
24/4/15
![Page 2: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/2.jpg)
“A treatment modality that would be without risk and available to all who would benefit from it”
“ a terminal illness is being replaced by a new and different chronic condition”
![Page 3: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/3.jpg)
Liver Transplantation
Issues• Whether patient needs LT?• When to refer or consider for LT?• Is patient suitable for LT?• Specific issues regarding recipient
![Page 4: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/4.jpg)
Liver Transplantation
Proportion of liver transplants for specific etiologies, 1992–2007O’Leary et al Gastroenterology 2008
![Page 5: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/5.jpg)
Indications and Contraindications
![Page 6: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/6.jpg)
Indications Of Liver Transplantation: ESLD
1. Gastro esophageal variceal bleed-
each episode of bleeding carries a 20% mortaliity
rate. LT is the best way to decompress the portal
system if other therapies have failed. – De Francis et al, Baveno V, J Hepatology, 2010]
2. Hepatic encephalopathy
LT remains the only permanent Rx
![Page 7: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/7.jpg)
Indications Of Liver Transplantation: ESLD
3. Refractory ascites-
- carries a mortality of >50% at 2 yrs.
- More prone for variceal bleed, HRS, SBP.
- Annual incidence of HRS in cirrhotics with ascites is 8% with
median survival of 2 wks in Type I and 6 months in Type II.
- LT should be considered as soon as HRS is diagnosed.
Planas et al, Clini gastro hepatology 2006;4:1385-94Gines A et al, Gastroenterology 1993;105:229-36
![Page 8: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/8.jpg)
Indications Of Liver Transplantation: ESLD
4. Hepatopulmonary syndrome
-4-47%
- LT is the only curative Rx for HPS
5. Portopulmonary Hypertension
-2-8%,
- associated with higher post transplantation mortality
![Page 9: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/9.jpg)
Need For Liver Transplantation
• CTP and MELD most commonly used• 5-year survival (CTP 7-15) with (ascites,
bleeding, HE, SBP, HRS) : 20% to 50%• Survival rates 1, 3, and 5 years after LT 88%,
80%, and 75%-Shetty K et al Hepatology 1997
-Kamath PS et al Hepatology 2001
-Freeman RB et al Liver Transpl 2004-H-C Huang et al. Journal of Gastroenterology and Hepatology 24 (2009) 1716–1724
![Page 10: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/10.jpg)
• Comparison of mortality risk expressed as hazard ratio by MELD score for recipients of liver transplants compared to candidates on the liver transplant waiting list
– Merion et al, Am J transplantation 2005;5:307-13
In pts with MELD<14, the mortality with LTx > not undergoing LTx
![Page 11: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/11.jpg)
When to refer patient for Liver Transplantation
• Refer for liver transplantation when (CTP > 7 and MELD > 10) or they experience their first major complication (ascites, bleeding, or HE)
AASLD:Karen F et al Hepatology 2005 Berg CL et al Gastroenterology 2007
![Page 12: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/12.jpg)
Upper Limit Of MELD
• The estimated survival for patients with MELD score > 25 was lower at 12 months (68.86% vs 39.13%).
– Ilka Fatima Ferreira Santana Boin et al, Arc Gastroenterol 2008
• In 11 studies (19,311 patients), high MELD score indicated poor post-LT mortality for cut off values of 24-40 points
– Cholongital et al, Liver transplantation 2006
![Page 13: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/13.jpg)
Process of Liver Transplant Evaluation
Referral To transplant center or hepatologist
Financial screeningSecure approval for evaluation
Medical evaluation
Hepatology assessment Confirm diagnosis and optimizemanagement
Laboratory testing
Assess hepatic synthetic function, renal function, viral serologies, markers of othercauses of liver disease, tumor markers, ABO-Rh blood typing; inulin clearance or 24-hour urine for creatinine clearance; urinalysisand urine drug screen
![Page 14: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/14.jpg)
Investigations
• HBsAg, Total anti HBc, HBV DNA• Anti HCV, HCV RNA• CMV IgG and IgM, VDRL, HIV• ANA, ASMA, p-ANCA, Anti LKM• Doppler USG( SPA), TPCT , MRCP• S.AFP, CEA, CA19.9• Iron studies, copper studies• Thyroid profile
![Page 15: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/15.jpg)
Investigations
• Lipid profile• 24 hr urine studies- Na, K, Creatinine, albumin• Pap smear in females• Blood c/s, urine c/s• Throat swab, b/l axilla c/s, groin c/s• PFT, CXR, ABG• ECG, 2D ECHO
![Page 16: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/16.jpg)
Transplant surgeryevaluation
Assess technical issues anddiscuss risks of procedure
Anesthesia evaluation Required if unusually high operativerisk, eg, portopulmonary hypertension, hypertrophic obstructive cardiomyopathy,previous anesthesia complications
Psychiatry or psychologyIf prior history of substance abuse,psychiatric illness, or adjustmentdifficulties
![Page 17: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/17.jpg)
Cardiao-pulmonary evaluation Electrocardiography,stress testing and cardiologyconsult if risk factors are present and/or age 40 years or older, pulmonologist opinion
Hepatic imaging USG with Doppler for portal vein patency,triple-phase CT/ gadolinium MRI for tumor screening
General healthassessment
Chest x-ray, prostate-specific antigen level (males), Pap smear and mammogram (females), colonoscopy if age 50 years orolder or PSC
![Page 18: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/18.jpg)
Social work Address potential psychosocial issues and possible impact of transplantation on patient’s personal and social system
Financial counseling Itemize costs of transplant and post transplant care, help develop financial management plans
Nutritional support Assess nutritional status and patient education
![Page 19: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/19.jpg)
Issues Regarding Recipient
• Does age matter?• HLA matching and ABO incompatibility• HIV status• Underlying cardiac status• Pulmonary status• Obesity and smoking• Diabetes Mellitus and Hypertension• Alcohol• Combined transplantation
![Page 20: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/20.jpg)
Age > 60 years
![Page 21: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/21.jpg)
Age > 60 yrs and Liver Transplantation
Gray bars equals Age<60; dark gray bars equal Elderly-Age > 60
Problems: more comobidities, increased chance of mortality due to malignancy, CAD
Benefits; low acute rejection rate, better graft survivalKeswani et al Liver Transplantation,2004
![Page 22: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/22.jpg)
HLA Matching : is it required?
• Not applied Patient pool is too small for matchingCold ischemia time is too shortMost liver transplants are performed for
reasons of urgency that overrides matching• ? Does that mean it does not have any effects
![Page 23: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/23.jpg)
HLA Matching
• The differences in the 6-month graft survival rates between the best and worst matched transplants were 6.6% for the A locus, 10.4% for the B locus, and 10.9% for the A, B loci
Transplant Proc. 1992
![Page 24: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/24.jpg)
ABO Incompatibilty
• Have become a viable option with development of newer immunosuppressant's and strategy
![Page 25: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/25.jpg)
ABO Incompatibility
• ABO incompatibility is associated with high risk of graft failure
• BW Kim et al showed use of Rituximab 375mg/m2 preoperatively on 15 and 8, as well as preoperative plasma exchange reduced humoral rejection in 3 ABO incompatible liver transplant.
BW Kim et al J.transproceed.2008
![Page 26: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/26.jpg)
ABO Incompatibility
• 1 year and 2 year survival 90%(in 10 cases) - Song GW et al, Transplant Proc.2013
• In a single centre experience, in 22 cases, Rituximab and plasmapheresis were used prior to LDLT and plasmapheresis was continued for upto 2 weeks after LDLT to maintain anti ABO titres below 1:32.
• Graft survival was 100 % at 10 months and no acute humoral rejection was noted
- Kim JM et al, J Hepatol 2013
![Page 27: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/27.jpg)
ABO Incompatibilty
• In a retrospective analysis of ABO incompatible liver transplants( n =22), rate of infections were higher in ABO – I transplants but rate of rejection , complications, cumulative survival was similar( 72.5.3 vs 72.9% at 1year, 69.1 vs 65.6 % at 3 years and 61.8 % vs 56.2% at 5 years.)
Shen Z et al. cma.j.issn.2014
![Page 28: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/28.jpg)
ABO Incompattibility
![Page 29: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/29.jpg)
HIV and Liver TransplantCriteria:• Absolute CD4 count >200 cells/mL and controllable HIV
viremia on HAART therapy.
Contraindication:• CD4+ counts <100/mL and multi-drug resistant HIV
• Short-term survival with HIV infection controlled with HAART comparable with HIV-negative recipients
• Requires well-coordinated, multidisciplinary team
HIV +ve status is not a contraindication for LT
Fung et al Liver transplantation 2004
![Page 30: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/30.jpg)
Evaluation of cardiac status
• High risk factorsDiabetesHypertensionNASHPeripheral vascular diseasePrevious CADAge > 50 yearsDyslipidemia Obesity
![Page 31: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/31.jpg)
Evaluation of cardiac status in LT recipients
Mandell et al World J gastro 2008, Shaw et al Radiology 2003
Asymptomatic Liver transplant candidate
No high risk factors High risk factors
Stress testing
Calcium Score
PositiveNegative
No further testing
Coronary angiography
0-1 risk factors 2 or more risk factors 3 or more risk factors
Negative Positive
![Page 32: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/32.jpg)
Coronary Artery Disease
Murray et al Hepatology 2005
• Dobutamine stress ECHO
• Confirmed by cardiac catheterization
![Page 33: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/33.jpg)
Portopulmonary Hypertension
• Portopulmonary(PoPH) hypertension is associated
with reduced survival: 1-year survival of
approximately 35 to 46% without treatment
• Risk of perioperative mortality after LT is increased in
patients with PoPH ( 35%)
• Right ventricular failure in susceptible patients with
PoPH(MPAP > 50 mm Hg) Krowka M J , Liver Transpl 2004
![Page 34: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/34.jpg)
Portopulmonary Hypertension
• Doppler ECHO : sensitive method• Positive test: confirmed with right heart
catheterization• Severe pulmonary HT >60 mmHg: post LT 70%
mortality by 3 yr• LT if effectively controlled(<45mmHg) with
medical therapy Ramsay MA et al Liver Transpl Surg 1997 Starkel P et al Liver Transpl 2002 Kim WR et al Liver Transpl 2000
![Page 35: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/35.jpg)
MAYO clinic algorithm
American Journal of Transplantation 2008; 8: 2445–2453
Screening Transthoracic Echocardiogram
RVSP >50 mm Hg? Re-Echo in 12 mo
Right Heart Catheterization ( with SvO2 full saturation run)
MPAP < 35 35 <= MPAP <= 50 50 < MPAP
> 240< 240 > 240< 240 > 240< 240
PVR
LT
OKOK OK NRRX
Yes
No
Contraindicated
![Page 36: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/36.jpg)
Hepatopulmonary Syndrome
• Every patient being evaluated for LT should be screened for HPS
• ABG, contrast echo, response to 100% oxygen, and quantification of shunting using MAA scan.
• Median survival of patients with severe HPS <12 months• PaO2 < 50 mmHg with a MAA shunt fraction >20%
predictors of postoperative mortality
AASLD• Expedited referral and evaluation for liver transplantation
Arguedas MR et al Hepatology 2003Collisson EA et al Liver transplantation 2002
![Page 37: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/37.jpg)
Prognosis of HPS: MAYO experience
![Page 38: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/38.jpg)
Eur Respir Mon 2011; 54: 246–264
Arterial blood gases
OLT candidatesHepatic disease patients with dyspnoea
No HPS
Pa,o2 < 80 mmHg(and/or)
PA-a,o2 >= 15 mmHg
CEE
Pa,o2 >= 80 mmHg
Negative CEE Positive CEE + PFTs
No HPS
Pa,o2 >=60 - < 80 mmHg(and/or)
PA-a,o2 >= 15 mmHgPa,o2 >=50 - <60 mmHg
Pa,o2 < 50 mmHg;MAA >=20%
Follow-up OLT OLT
![Page 39: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/39.jpg)
HPS:MELD exception
• HPS: PaO2 < 60 mmHg on room air will be listed at a MELD
score of 22 with a 10% mortality equivalent increase in points
every three months if the candidate’s PaO2 stays below 60
mmHg
• Preoperative PaO2 of 50 mmHg or less alone or in combination
with a MAA shunt fraction of 20% or more are the strongest
predictors of postoperative mortality AASLD Practice Guidelines 2005
Organ Procurement and Transplantation Network (OPTN) Policies
HEPATOLOGY 2003;37:192-197.
![Page 40: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/40.jpg)
Kidney-Liver Transplant if:
• Primary renal disease expected to cause renal failure within 3 years of transplant
• HRS with dialysis dependent renal failure lasting over 8 weeks
• Renal biopsy shows over 30% tubulointerstitial fibrosis or 40% glomerulosclerosis or moderate to severe arteriosclerosis
Grewal HP et al Transplantation 2000Rogers J et al Transplantation 2001
![Page 41: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/41.jpg)
Obesity
• Obesity is thought to affect prognosis of post liver transplant patients adversely.
• Difficult to determine in part due to confounding effect of ascites
• In a meta-analysis, no difference in mortality in patients with different BMI, however obese patients had worse prognosis than non obese patients in pooled analysis of studies which had similar causes of liver disease among obese and non obese patients
-Saab et al, liver int.2015
![Page 42: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/42.jpg)
Obesity
• Corrected BMI is not an independent predictive of patient or graft survival
- Leonard J et al, Am Transplant,2008
![Page 43: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/43.jpg)
ObesityNormal weight(n=643)
Overweight(n=417)
Obese(n=145)
Morbidly obese(n=73)
p value
Postoperative infectivecomplications
50.4% 60.7% 65.5% <.01
ICU stay 3.2 days 4.7 days <.01
Mean hospital stay 18days 22.4 days 21.3 days 22.4 days <.0001<.04<.05
Abdul R. Hakeem et al. Liver Transpl 2013
![Page 44: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/44.jpg)
Smoking
• Those who quit smoking for more than six months had
complications rates similar to those who had never smoked (11%
vs. 11.9%)
• Smoking history of 40 pack years or more was strongly associated
with increased risk of pulmonary complications
• Risk of hepatic artery thrombosis appears to be significantly
increased among chronic smokers
Anaestheseology 1984;60:380-3
Am J Respir Crit Care Med 2003;167:741-4
Liver Transpl 2002;8:582-587.
![Page 45: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/45.jpg)
Diabetes In Recipients
![Page 46: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/46.jpg)
Diabetes in Recipients
• Type 1 diabetes mellitus have 40 % lower 5 year survival as compared to those without it
• Type 2 diabetes mellitus was not an independent predictor of survival but had 27 % more risk of having postoperative infective complication
Yoo et al, Transplantation.2002
![Page 47: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/47.jpg)
Liver Transplantation in patients with Tuberculosis
• Active tuberculosis is a contraindication• But no option if indication is fulminant hepatic
failure• In a series of 9 patients with such scenario, patients
were treated with modified ATT after LDLT.• All patients were treated successfully and followed
for median of 926 days without relapse Lee YT et al, Int J Tuberc Lung Dis.2010
![Page 48: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/48.jpg)
Tuberculosis screening for LT
• Prevalence of TB infection in liver transplant
recipients :1% to 6%
• The mortality rate : 40% despite treatment;
without treatment it is 100%
• Positivity (TT ≥ 5 mm) occurs among up to 25%:
4-fold risk for tuberculosis after LTTransplantation 83:1536, 2007
![Page 49: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/49.jpg)
Liver transplant in Alcoholics
• 6 month period of abstinence ? • 50 % of patients go back to some form of
alcoholism after transplant• NHS first allowed listing of alcoholics with
severe liver disease for transplant listing in 2014 in UK
• This major shift in policy was inspired by landmark study published in NEJM in 2011
![Page 50: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/50.jpg)
![Page 51: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/51.jpg)
The ideal LDLT recipient profileListing Must first be listed on DD waiting list (Meets UNOS)
MELD score <25
Recipient risk factors No thrombosis of multiple visceral veins/ multiple medical problems/ multiple significant abdominal surgeries; advanced age
Specific recipient subgroups
HCC Benefit substantially from rapid LDLT as DDLT may allow for metastasis
Severity of illness not reflected by MELD score
Complicated cholestatic liver disease, patients with ascites, uncontrolled HE and/ or severe cachexia, HPS,PP hypertension
![Page 52: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/52.jpg)
Donor Evaluation
![Page 53: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/53.jpg)
Objectives of the Evaluation
• Provide all relevant information to donor to facilitate the right decision in order to make a voluntary donation without any pressure
• Donor’s interest should be protected
• Advocates of donor safety
![Page 54: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/54.jpg)
The Ideal Living Liver Donor
• Between the ages of 18 and 50• A family member such as a spouse, parent,
sibling, child, nephew or niece or a friend • The same or compatible blood type as the
recipient• BMI <28 • In excellent medical and psychological health• Highly motivated
![Page 55: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/55.jpg)
Swap/Domino Liver Transplant• Swap liver transplant- method to match the blood
group incompatible donor and recipient couples with the couples having same problems
• Domino Liver transplant- in patients with familial amyloidosis(FAP)
• Patient receives liver and his own liver( physiologically normal but with defective gene) is transplanted to another patient
• The recipient will take decades(2-3) to develop amyloidosis
• Only 2 out of 500 patients developed amyloidosis Ericzon et al, Transplant
Proc.2008
![Page 56: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/56.jpg)
Contraindications
• Previous liver surgery• HIV infection• Viral hepatitis• History of cancer• Heart and lung disease• Diabetes• Active alcoholism• Psychiatric problems
![Page 57: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/57.jpg)
Extended Donors
• ABO incompatible• Anti HBc antibody positive but HBsAg -• Chronic hepatitis C?• Marginal donors- Donors with steatosis 10- 40%- Donors with significant alcohol consumption- Cadaveric donors with possible sepsis, transient
hypotension and transient abnormal liver function test
![Page 58: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/58.jpg)
Approach to Donor with fatty liver
• 78 % of potential donors with a BMI > 28 had hepatic steatosis (>10% steatosis) on liver biopsy-
Rinella et al.Liver Transpl 2001
• Most centers exclude donors who have > 10% of steatosis as hepatic steatosis is associated with poor posttransplantation graft function
• Obesity also increases risk of complications with donor surgery
• Also, obese people are more likely to have comorbid conditions
![Page 59: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/59.jpg)
Approach to donor with fatty liverDonor with no fatty change
10-30% steatosis
30-60% steatosis
P value
3 month survival in recipient
68% 72% 76% >.05
Hospital stay 30.89 days 29.93 days 23.62 days >.05
ICU stay 5.06 days 5.89 days 4.39 days >.05
Nikeghbalian S, Transplant Proc. 2007
![Page 60: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/60.jpg)
Liver biopsy in potential Donor
• Some centers do liver biopsy in all• Others do when 1) BMI > 28 kg/m22)significant alcohol intake3) elevated serum ferritin levels4) presence of steatosis on imaging5) HBV core positive serology• Liver biopsy determines presence and extent of
hepatic steatosis
![Page 61: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/61.jpg)
Liver biopsy in potential Donor
• Protocol liver biopsy in all detects abnormal liver biopsy in upto 73% donors but most of them were non specific/not significant e.g steatosis < 10%.
Tran T et al. Gastroenterology 2003
![Page 62: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/62.jpg)
Donor suitability
• Are the intentions authentic?
– No evidence of gross financial disparity between donor and recipient especially in unrelated donation
![Page 63: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/63.jpg)
• Are the implications of LDLT in terms of risks and benefits clearly understood?
– Mortality of one in 250-300 cases– Morbidity of up to 10% including bleeding,
biliary, wound complications– Clear discussion of risk, benefit, ethical
issues involved
![Page 64: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/64.jpg)
Donor Evaluation – Step Wise
• Step 1 – Consultation and Clinical Examination– With donor alone and – With close relative
• Donor willingness• Motivation• Offer for walk out on clinical reason – to protect relationship
• Step 2 – After work up – if donor is suitable match– Psychiatric evaluation
• Step 3 – Days prior to operation – with donor alone
![Page 65: Pre Liver Transplant Evaluation 24/4/15. “A treatment modality that would be without risk and available to all who would benefit from it” “ a terminal.](https://reader035.fdocuments.in/reader035/viewer/2022062717/56649e565503460f94b4df02/html5/thumbnails/65.jpg)
THANK YOU